Events on 28 September 2023

EQA of Autoimmunity

Immunology online Specialist Diploma programme

This presentation will cover a case study completed as part of the IBMS Specialist Diploma in Immunology in 2022. It will be of interest to anyone considering completing the Higher Specialist Diploma in Immunology, or anyone who would like to learn more about the case study element. It will also be of interest to anyone who would like to learn more about the protocols used for reading and reporting methods including immunophenotyping by flow cytometry, serum protein electrophoresis and immunotyping, serum free light chains and Bence Jones protein analysis at Greater Manchester Immunology Service (GMIS).

The case is one of an elderly gentleman with who, like roughly a third of new myeloma cases in the UK, presented through A&E. The presentation will cover pre-analysis, analysis and post-analysis, considering how the tests performed in the Immunology laboratory assist in the differential diagnosis and where they fit in with the other tests ordered, both tests within and outside of the Immunology discipline. The presentation will cover the methods performed at GMIS and some of the reporting protocols, as well as discussing some of the relevant associated guidelines.

This cases study focusses on a paient that showed dual positivity for Anti-GBM and Anti-PLA2r antibodies. It will look at how testing was requested, the methods used for the investigations and how the results lead to the conclusions drawn.

It will also look at testing algorithms in the Immunology laboratory, related to these investigations and how these could be improved.

Myositis

Scleroderma

Chronic lung infection is the leading cause of morbidity and early mortality for people with cystic fibrosis (pwCF). Microbiological surveillance to detect lung pathogens is recommended as best practise in CF patient care. Here we studied pathogen detection in forty pwCF over several years. We found that microbiological culture, the diagnostic gold standard, was significantly disparate to targeted culture-independent approaches for detection and determination of chronic infection status of two important pathogens in CF. Pathogen detection was significantly lower by culture and consequently infection status was also misclassified in the majority of cases.

In particular, the extent of chronic infection by both Pseudomonas aeruginosa and Staphylococcus aureus not realised with culture was striking. Our findings have implications for the development of infection and clinical care of pwCF. Future longitudinal studies with greater patient numbers will be needed to establish the full extent of the clinical implications indicated from this study.

Shiga toxin-producing Escherichia coli (STEC) O157:H7 has been the most clinically significant STEC serotype in the UK for over four decades. However, over the last 10 years we have observed a decrease in STEC O157:H7 and an increase in non-O157 STEC serotypes, such as O26:H11. Little is known about the microbiology and epidemiology of non-O157 STEC. This presentation describes the virulence, clinical outcomes and epidemiology of non-O157 STEC, focusing on the most commonly detected serotype, STEC O26:H11.

This presentation will give delegates a:

Real world evaluation of a syndromic panel compared to traditional Gram stain and culture
The presentation will cover:

An outline of the trial
A summary of findings
The local experience of the process
Brief local case studies that show how the multiplex PCR panel results could have positively affected patient management.

Increasing antimicrobial resistance observed globally in key Gram-negative bacteria and failure of the antimicrobial development pipeline to keep up has left clinicians with few remaining treatment options. This presentation will: i) highlight the current gaps in our antimicrobial armamentarium (with a focus on the World Health Organisation critical priority pathogens); ii) give an overview of new antimicrobials that have reached phase 3 clinical trials and other therapeutic approaches currently in the pipeline; and iii) share experience from the reference laboratory.